Talis Biomedical Bilan de santé

Santé financière contrôle des critères 6/6

Talis Biomedical possède un total de capitaux propres de $48.6M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $72.7M et de $24.1M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$59.87m
Fonds propres	US$48.63m
Total du passif	US$24.07m
Total des actifs	US$72.70m

Mises à jour récentes de la santé financière

We're A Little Worried About Talis Biomedical's (NASDAQ:TLIS) Cash Burn Rate

Aug 16

Recent updates

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Nov 04

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Jul 21

News Flash: 4 Analysts Think Talis Biomedical Corporation (NASDAQ:TLIS) Earnings Are Under Threat

May 18

Talis Biomedical Corporation (NASDAQ:TLIS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 14

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de TLIS ( $63.6M ) dépassent ses passifs à court terme ( $8.2M ).

Passif à long terme: Les actifs à court terme de TLIS ( $63.6M ) dépassent ses passifs à long terme ( $15.9M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: TLIS est sans dette.

Réduire la dette: TLIS n'a eu aucune dette au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: TLIS dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: TLIS dispose d'une marge de trésorerie suffisante pour 1.1 ans si le flux de trésorerie disponible continue de croître à un taux historique de 0.8 % chaque année.

Talis Biomedical Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Talis Biomedical Corporation Files Form 15

Talis Biomedical Receives Non-Compliance Letter from Nasdaq Regarding Nasdaq Listing Rule 5101

Talis Biomedical Corporation announced delayed 10-Q filing

Talis Biomedical Announces 1-For-15 Reverse Stock Split to Regain Compliance

Talis Biomedical Transfers the Listing of Its Securities to the Nasdaq Capital Market

We're A Little Worried About Talis Biomedical's (NASDAQ:TLIS) Cash Burn Rate

Recent updates

Talis Biomedical Corporation Files Form 15

Talis Biomedical Corporation(OTCPK:TLIS) dropped from NASDAQ Composite Index

Talis Biomedical Receives Non-Compliance Letter from Nasdaq Regarding Nasdaq Listing Rule 5101

Talis Biomedical Corporation announced delayed 10-Q filing

Talis Biomedical Corporation to Report Q2, 2023 Results on Aug 10, 2023

Talis Biomedical Corporation Announces New Data Supporting the Development of Its Planned CT/NG/TV and Vinal Infections Panels

Talis Biomedical Announces 1-For-15 Reverse Stock Split to Regain Compliance

Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors

Talis Biomedical Corporation Appoints Kimberly Popovits as Lead Independent Director

Talis Biomedical Corporation to Report Q1, 2023 Results on May 11, 2023

Talis Biomedical Transfers the Listing of Its Securities to the Nasdaq Capital Market

Price target decreased to US$0.40

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.98 loss per share (vs US$1.49 loss in 3Q 2021)

We're A Little Worried About Talis Biomedical's (NASDAQ:TLIS) Cash Burn Rate

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Talis Biomedical reports Q2 results

Talis Biomedical Corporation Announces Resignation of Raymond Cheong from Board of Directors

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$1.25

Less than half of directors are independent

Talis Biomedical Corporation Announces Board Changes

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Talis Biomedical Aims For Manufacturing Turnaround

Talis Biomedical Corporation to Report Q4, 2021 Results on Mar 15, 2022

The Klein Law Firm Announces Lead Plaintiff Deadline of March 8, 2022 in the Class Action Filed on Behalf of Talis Biomedical Corporation Shareholders

Talis Biomedical (NASDAQ:TLIS) Will Have To Spend Its Cash Wisely

Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Filed Against Talis Biomedical Corporation

Levi & Korsinsky, LLP Notifies Shareholders of Talis Biomedical Corporation of A Class Action Lawsuit and A Lead Plaintiff Deadline

Glancy Prongay & Murray LLP Files Securities Lawsuit Against Talis Biomedical Corporation

Less than half of directors are independent

Third quarter 2021 earnings released: US$1.48 loss per share (vs US$13.90 loss in 3Q 2020)

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Consensus revenue estimates fall to US$11.2m

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Talis Biomedical Corporation(NasdaqGM:TLIS) dropped from Russell Microcap Growth Index

Independent Director recently bought US$203k worth of stock

News Flash: 4 Analysts Think Talis Biomedical Corporation (NASDAQ:TLIS) Earnings Are Under Threat

Talis Biomedical Corporation (NASDAQ:TLIS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2021 earnings released: US$4.61 loss per share (vs US$56.61 profit in 1Q 2020)

Full year 2020 earnings released: US$42.98 loss per share (vs US$34.34 profit in FY 2019)

Talis Appoints Jeryl Hilleman to Board of Directors

Talis Biomedical Corporation Provides Update on Regulatory Pathway for Emergency Use Authorization (EUA) of Its Talis One™ Covid-19 Test

Talis Biomedical Corporation has completed an IPO in the amount of $220.8 million.

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines